Details of Disease

General Information of Disease (ID: DIS71F6X)

• Disease Name: Cholangiocarcinoma
• Synonyms: bile duct cancer; intrahepatic bile duct cancer (cholangiocarcinoma); adult primary cholangiocellular carcinoma; CCA; Cholangiocellular carcinoma; Cholangiocar.- intra/extrahepatic; cholangiocarcinoma, intrahepatic and extrahepatic bile ducts (adenocarcinoma); CC; adult primary cholangiocarcinoma; cholangiosarcoma; cholangiocarcinoma; cholangiocarcinoma, malignant
• Disease Class: 2C12: Liver cancer
• Definition: A carcinoma that arises from the intrahepatic biliary tree (intrahepatic cholangiocarcinoma) or from the junction, or adjacent to the junction, of the right and left hepatic ducts (hilar cholangiocarcinoma). Grossly, the malignant lesions are solid, nodular, and grayish. Morphologically, the vast majority of cases are adenocarcinomas. Signs and symptoms include malaise, weight loss, right upper quadrant abdominal pain, and night sweats. Early detection is difficult and the prognosis is generally poor.
• Disease Hierarchy:
  DISWBR2H: Adenocarcinoma of gallbladder and extrahepatic biliary tract
  DISH9F1N: Carcinoma
  DIS71F6X: Cholangiocarcinoma
• ICD Code:
  ICD-11: ICD-11: 2C12.10
  ICD-10: ICD-10: C22.1
  Expand ICD-11: 'XH7M15
• Disease Identifiers:
  MONDO ID: MONDO_0019087
  MESH ID: D018281
  UMLS CUI: C0206698
  MedGen ID: 60210
  HPO ID: HP:0030153
  Orphanet ID: 70567
  SNOMED CT ID: 312104005

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 8 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bevacizumab	DMSD1UN	Approved	Monoclonal antibody	[1]
Carboplatin	DMG281S	Approved	Small molecular drug	[2]
Futibatinib	DMWM4D0	Approved	NA	[3]
Gemcitabine	DMSE3I7	Approved	Small molecular drug	[4]
Infigratinib	DMNKBEC	Approved	Small molecular drug	[5]
Ivosidenib	DM8S6T7	Approved	NA	[6]
Oxaliplatin	DMQNWRD	Approved	Small molecular drug	[7]
Pemigatinib	DM819JF	Approved	NA	[8]

This Disease is Treated as An Indication in 6 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ABC294640	DMCKPG4	Phase 3	Small molecular drug	[9]
ARQ-087	DM02BVQ	Phase 3	NA	[10]
BBI503	DMDSNIR	Phase 2	NA	[11]
CX-4945	DMWE7B9	Phase 2	Small molecular drug	[9]
DKN-01	DMOHT5V	Phase 2	Antibody	[12]
TC-210	DM9S5I1	Phase 1/2	TCR-T cell therapy	[13]

This Disease is Treated as An Indication in 2 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PAN-622-toxin conjugate	DMWUZPE	Investigative	NA	[14]
Silmitasertib	DMQIBZD	Investigative	Small molecular drug	[15]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 125 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
MAOA	TT3WG5C	Limited	Biomarker	[16]
PRKACA	TT5U49F	Limited	Biomarker	[17]
ABCC3	TTVLG21	moderate	Altered Expression	[18]
HGF	TT4V2JM	moderate	Biomarker	[19]
MUC1	TTBHFYQ	moderate	Biomarker	[20]
TUSC2	TTJ8O14	moderate	Genetic Variation	[21]
ABCB11	TTUXCAF	Strong	Genetic Variation	[22]
ABCB4	TTJUXV6	Strong	Genetic Variation	[23]
ABCC2	TTFLHJV	Strong	Biomarker	[18]
ABCG1	TTMWDGU	Strong	Biomarker	[24]
AICDA	TTKRTP6	Strong	Altered Expression	[25]
APLNR	TTJ8E43	Strong	Biomarker	[26]
ASPH	TT2KHP7	Strong	Biomarker	[27]
BAP1	TT47RXJ	Strong	Biomarker	[28]
BBC3	TT7JUKC	Strong	Altered Expression	[29]
BRAF	TT0EOB8	Strong	Genetic Variation	[30]
CBR1	TTVG0SN	Strong	Biomarker	[31]
CCNB1	TT9P6OW	Strong	Altered Expression	[32]
CDA	TTQ12RK	Strong	Genetic Variation	[33]
CDH6	TT9QHUK	Strong	Biomarker	[34]
CDK7	TTQYF7G	Strong	Biomarker	[35]
CEACAM3	TTPX7I5	Strong	Altered Expression	[36]
CEACAM6	TTIGH2W	Strong	Biomarker	[37]
CHRNA4	TT4H1MQ	Strong	Altered Expression	[38]
CLDN18	TT6PKBX	Strong	Altered Expression	[39]
COPS5	TTSTNJR	Strong	Biomarker	[40]
CRYZ	TTP6UO8	Strong	Biomarker	[41]
DCLK1	TTOHTCY	Strong	Biomarker	[42]
DNAJB1	TTPXAWS	Strong	Biomarker	[43]
EED	TTFNJ4R	Strong	Biomarker	[44]
EGFL7	TT7WD0H	Strong	Altered Expression	[45]
EGFR	TTGKNB4	Strong	Biomarker	[46]
ELAVL1	TTPC9D0	Strong	Altered Expression	[47]
EPCAM	TTZ8WH4	Strong	Altered Expression	[48]
EPO	TTQG4NR	Strong	Biomarker	[49]
EPOR	TTAUX24	Strong	Biomarker	[49]
ERBB2	TTR5TV4	Strong	Altered Expression	[50]
FFAR4	TT08JVB	Strong	Biomarker	[51]
FGF19	TTGCH11	Strong	Biomarker	[52]
FGFR2	TTGJVQM	Strong	Biomarker	[53]
FLT4	TTDCBX5	Strong	Biomarker	[54]
FOLH1	TT9G4N0	Strong	Altered Expression	[55]
FSCN1	TTTRS9B	Strong	Biomarker	[56]
FUT3	TTUPAD7	Strong	Genetic Variation	[57]
GADD45B	TTMDW9L	Strong	Biomarker	[58]
GALNS	TTT9YPO	Strong	Altered Expression	[59]
GPBAR1	TTSDVTR	Strong	Altered Expression	[60]
GPC3	TTJTSX4	Strong	Biomarker	[61]
GSTA3	TT29VDX	Strong	Biomarker	[62]
HDAC3	TT4YWTO	Strong	Altered Expression	[63]
HK2	TTK02H8	Strong	Biomarker	[64]
HMBS	TTT0HW3	Strong	Altered Expression	[65]
HRH3	TT9JNIC	Strong	Biomarker	[66]
HSP90B1	TTFPKXQ	Strong	Genetic Variation	[67]
HTATIP2	TTC6IX5	Strong	Biomarker	[68]
HTR1A	TTSQIFT	Strong	Biomarker	[69]
IDH1	TTV2A1R	Strong	Genetic Variation	[70]
IL6	TTT1V78	Strong	Biomarker	[71]
IRF1	TT4TU3L	Strong	Biomarker	[72]
KHDRBS1	TTAT6C7	Strong	Altered Expression	[73]
KRAS	TTM8FR7	Strong	Biomarker	[74]
KRT19	TT3JF9E	Strong	Biomarker	[75]
LASP1	TTZJA87	Strong	Altered Expression	[76]
LCK	TT860QF	Strong	Biomarker	[77]
LOXL2	TTFSUHX	Strong	Altered Expression	[78]
MAGEA1	TT63M7Q	Strong	Biomarker	[79]
MAGEA3	TTWSKHD	Strong	Biomarker	[79]
MAP2K2	TT8H9GB	Strong	Altered Expression	[80]
MAP3K1	TTW8TJI	Strong	Genetic Variation	[81]
MARCKS	TTHRM39	Strong	Altered Expression	[82]
MCM7	TT1RM3F	Strong	Biomarker	[83]
METAP2	TTZL0OI	Strong	Biomarker	[84]
MMP2	TTLM12X	Strong	Altered Expression	[85]
MSLN	TT4RXME	Strong	Altered Expression	[86]
MUC16	TTC1PS3	Strong	Biomarker	[87]
MUC5AC	TTEL90S	Strong	Biomarker	[88]
MUTYH	TTNB0ZK	Strong	Genetic Variation	[89]
NEK2	TT3VZ24	Strong	Altered Expression	[90]
NEK8	TT8AH9I	Strong	Biomarker	[91]
NOS2	TTF10I9	Strong	Biomarker	[92]
NR0B2	TT25A9Q	Strong	Biomarker	[93]
NR1H4	TTS4UGC	Strong	Biomarker	[94]
NUAK1	TT65FL0	Strong	Altered Expression	[95]
PBRM1	TTH8ZRL	Strong	Genetic Variation	[96]
PDGFD	TTSN0GA	Strong	Biomarker	[97]
PDX1	TT8SGZK	Strong	Altered Expression	[98]
PHB	TT6U071	Strong	Biomarker	[99]
PKD2L1	TTAHD89	Strong	Biomarker	[54]
PKM	TT4LOT8	Strong	Altered Expression	[100]
PPIA	TTL2ADK	Strong	Altered Expression	[101]
PPP5C	TTTW7FJ	Strong	Biomarker	[102]
PRKCI	TTWJTHX	Strong	Altered Expression	[103]
PTEN	TTXJ3W7	Strong	Biomarker	[104]
PTGER1	TTG1QMU	Strong	Biomarker	[85]
PTGS2	TTVKILB	Strong	Biomarker	[105]
PTK6	TT6TH8V	Strong	Altered Expression	[73]
PTPN6	TT369M5	Strong	Biomarker	[93]
RAB7A	TTF6WAQ	Strong	Biomarker	[106]
RARG	TT1Q3IE	Strong	Biomarker	[107]
RNF43	TTD91BL	Strong	Biomarker	[108]
ROS1	TTSZ6Y3	Strong	Biomarker	[109]
RPSA	TTLUW5B	Strong	Altered Expression	[110]
S1PR2	TTVSMOH	Strong	Altered Expression	[111]
SCGB1A1	TTONPVW	Strong	Biomarker	[112]
SEMA4D	TT5UT28	Strong	Biomarker	[113]
SLC11A2	TT2IS7P	Strong	Biomarker	[114]
SLC22A1	TTM5Q4V	Strong	Posttranslational Modification	[115]
SLC22A2	TT0XOJN	Strong	Biomarker	[116]
SLC23A2	TTOP832	Strong	Altered Expression	[117]
SLC38A1	TT1YE9Z	Strong	Biomarker	[118]
SLC3A2	TT5CZSM	Strong	Altered Expression	[119]
SLC5A5	TTW7HI9	Strong	Altered Expression	[120]
SLC7A5	TTPH2JB	Strong	Altered Expression	[119]
SSTR2	TTZ6T9E	Strong	Biomarker	[121]
TACC3	TTQ4UFD	Strong	Altered Expression	[122]
TACSTD2	TTP2HE5	Strong	Biomarker	[123]
TFF1	TTNOJIZ	Strong	Biomarker	[124]
TGFBR2	TTZE3P7	Strong	Genetic Variation	[125]
TNC	TTUCPMY	Strong	ModifyingMutation	[126]
TNFRSF18	TTG6LA7	Strong	Biomarker	[127]
TPH1	TTZSJHV	Strong	Altered Expression	[128]
TRIM59	TT613U4	Strong	Biomarker	[129]
TRIP10	TTKHTGE	Strong	Genetic Variation	[130]
UMPS	TTAFJUD	Strong	Altered Expression	[131]
USP14	TTVSYP9	Strong	Altered Expression	[132]

This Disease Is Related to 2 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC4A1	DTB0Q3P	Strong	Biomarker	[133]
SLC4A2	DTF7GAL	Strong	Biomarker	[134]

This Disease Is Related to 7 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CES2	DETHCPD	Strong	Biomarker	[135]
GGCT	DEKW6PB	Strong	Biomarker	[136]
HPGD	DEHKSC6	Strong	Biomarker	[137]
NAT1	DE7OAB3	Strong	Biomarker	[138]
PER1	DE9HF0I	Strong	Biomarker	[139]
SULT1A1	DEYWLRK	Strong	Genetic Variation	[130]
UGT1A10	DEL5N6Y	Strong	Altered Expression	[140]

This Disease Is Related to 188 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
GPC1	OTQKRSSV	Limited	Altered Expression	[141]
KMT2C	OTC59BCO	Limited	Biomarker	[108]
MAFG	OTBQFUZH	Limited	Altered Expression	[142]
NCOA1	OTLIUJQD	Limited	Altered Expression	[143]
PEG3	OTHQW98S	Limited	Biomarker	[108]
ROBO2	OTFJ9FQW	Limited	Biomarker	[108]
SRA1	OTYOGMTG	Limited	Altered Expression	[143]
ALX4	OTNS9A29	moderate	Biomarker	[144]
ARHGAP24	OTCQCEZS	moderate	Genetic Variation	[145]
ASAP1	OT4DLRYY	moderate	Genetic Variation	[21]
ASAP2	OTGEXULW	moderate	Genetic Variation	[21]
MRPS30	OTDXIAGG	moderate	Genetic Variation	[21]
MTPAP	OT6HQ02S	moderate	Genetic Variation	[21]
PAPOLA	OTPHD65D	moderate	Genetic Variation	[21]
PDAP1	OTJSWMOD	moderate	Genetic Variation	[21]
REST	OTLL92LQ	moderate	Altered Expression	[146]
AADAC	OT8VACT2	Strong	Posttranslational Modification	[147]
ABCG8	OTIJ76XW	Strong	Genetic Variation	[148]
ABI2	OT8GIIS5	Strong	Biomarker	[149]
ACAD8	OT3JI5GB	Strong	Biomarker	[150]
ACTRT1	OTHFKSIZ	Strong	Biomarker	[149]
AFAP1	OTR473H8	Strong	Biomarker	[151]
AGR3	OTONJPDP	Strong	Biomarker	[152]
AKIRIN2	OTQ6WSKW	Strong	Biomarker	[71]
ALDH1A3	OT1C9NKQ	Strong	Biomarker	[153]
ALDOA	OTWRFTIB	Strong	Altered Expression	[154]
ANXA4	OTUCRYXL	Strong	Biomarker	[155]
AP2A1	OTEFZB21	Strong	Biomarker	[156]
ARID1A	OTRWDV3P	Strong	Altered Expression	[157]
ARL6IP1	OT536XAV	Strong	Biomarker	[149]
ATP8B1	OTALGS63	Strong	Genetic Variation	[22]
AZIN2	OT8OB7CG	Strong	Biomarker	[158]
BCL9	OTRBIPR4	Strong	Biomarker	[159]
BHLHE22	OTZUQY5L	Strong	Biomarker	[160]
C1QL3	OT4TZH3J	Strong	Genetic Variation	[161]
CA10	OTC3N1F6	Strong	Biomarker	[162]
CBX5	OT8VYY84	Strong	Altered Expression	[163]
CCDC25	OTNC58MD	Strong	Altered Expression	[164]
CDKL3	OTJ0TQ9T	Strong	Biomarker	[165]
CDO1	OTLG1P77	Strong	Genetic Variation	[166]
CDX1	OTOHTMJE	Strong	Altered Expression	[167]
CDX2	OTCG4TSY	Strong	Biomarker	[168]
CEACAM7	OTKFDTZY	Strong	Altered Expression	[36]
CETN1	OTGQ8JOZ	Strong	Genetic Variation	[169]
CHD1L	OT7CZK7C	Strong	Altered Expression	[170]
CKS1B	OTNUPLUJ	Strong	Altered Expression	[171]
CKS2	OTPTMHIV	Strong	Biomarker	[172]
CLTC	OTBFASMA	Strong	Biomarker	[133]
COMMD6	OTRZQJFW	Strong	Altered Expression	[167]
COPB2	OT82JIGC	Strong	Altered Expression	[173]
CREB5	OTJDUJPI	Strong	Biomarker	[174]
CRTC3	OTVIGVUW	Strong	Genetic Variation	[175]
CSNK2B	OT2WW7R1	Strong	Biomarker	[176]
CUL4B	OT2QX4DO	Strong	Biomarker	[177]
DAB2IP	OTF456VC	Strong	Biomarker	[149]
DAPK1	OTNCNUCO	Strong	Biomarker	[178]
DCAF12	OT24XM7T	Strong	Biomarker	[179]
DCC	OT2C1SHW	Strong	Biomarker	[180]
DCTN4	OTM7C943	Strong	Genetic Variation	[181]
DCTN6	OTI8PIN9	Strong	Biomarker	[182]
DLC1	OTP8LMCR	Strong	Biomarker	[34]
DLEC1	OTMKKBUW	Strong	Posttranslational Modification	[183]
DMBT1	OTVNU9D9	Strong	Altered Expression	[184]
DPY30	OTLHCJ6C	Strong	Biomarker	[185]
DYNLL1	OTR69LHT	Strong	Posttranslational Modification	[183]
EBAG9	OTTQLQCP	Strong	Altered Expression	[186]
ECM1	OT1K65VW	Strong	Altered Expression	[187]
EPS8	OTZ6ES6V	Strong	Biomarker	[155]
ERBIN	OTNWTUA8	Strong	Biomarker	[188]
ERO1A	OTVKOQWM	Strong	Altered Expression	[189]
ETV4	OT8C98UZ	Strong	Altered Expression	[190]
FANCC	OTTIDM3P	Strong	Biomarker	[191]
FBN2	OT3KYJQL	Strong	Genetic Variation	[192]
FBP1	OTQBANEP	Strong	Biomarker	[193]
FBXW4	OTEGSZOX	Strong	Posttranslational Modification	[147]
FUT1	OTODG57A	Strong	Biomarker	[194]
FUT2	OTLXM6WI	Strong	Genetic Variation	[57]
GADL1	OTJM4A0R	Strong	Biomarker	[158]
GATA5	OTO81B63	Strong	Biomarker	[195]
GATA6	OTO2BC0F	Strong	Altered Expression	[78]
GFER	OTVK43OK	Strong	Altered Expression	[196]
GNAS	OTMH8BKJ	Strong	Biomarker	[108]
GNB3	OTA6HYBA	Strong	Genetic Variation	[197]
GNMT	OT0O2OQO	Strong	Biomarker	[198]
GOLM1	OTOZSV6O	Strong	Biomarker	[155]
GSTM3	OTLA2WJT	Strong	Biomarker	[199]
HHEX	OTLIUVYX	Strong	Genetic Variation	[200]
HOXB7	OTC7WYU8	Strong	Altered Expression	[201]
HOXD10	OT0NOWU2	Strong	Altered Expression	[202]
HOXD9	OTZ4GVR1	Strong	Biomarker	[203]
HSDL2	OT4IN0MV	Strong	Altered Expression	[204]
ID3	OTUULW5Z	Strong	Altered Expression	[205]
IDH2	OTTQA4PB	Strong	Genetic Variation	[206]
IFI27	OTI2XGIT	Strong	Altered Expression	[207]
IGBP1	OTTHH4YE	Strong	Biomarker	[208]
IGF2BP3	OTB97VIK	Strong	Altered Expression	[201]
INTU	OTXB13E6	Strong	Biomarker	[209]
ITGA9	OTHN1IKA	Strong	Biomarker	[210]
KLHL1	OTAX6SAD	Strong	Biomarker	[18]
KLHL21	OT28Y2LQ	Strong	Biomarker	[211]
KPNA2	OTU7FOE6	Strong	Biomarker	[212]
KRT18	OTVLQFIP	Strong	Biomarker	[213]
LAT	OTZC1XZ1	Strong	Altered Expression	[214]
LRG1	OTLD0KWA	Strong	Biomarker	[88]
MACC1	OTV3DLX0	Strong	Altered Expression	[215]
MAGED4B	OTO37U7W	Strong	Biomarker	[79]
MAGEH1	OTVE05K7	Strong	Altered Expression	[171]
MAGI2	OTXDDKZS	Strong	Biomarker	[149]
MAPK13	OT0W9GE7	Strong	Biomarker	[216]
MCM3AP	OT895FEC	Strong	Altered Expression	[217]
MFAP5	OT46VXSG	Strong	Altered Expression	[218]
MORC2	OT52A8BJ	Strong	Biomarker	[219]
MPC1	OT6DYFUO	Strong	Altered Expression	[220]
MSX2	OT1WDKE1	Strong	Altered Expression	[221]
MUC2	OT3X4QVX	Strong	Biomarker	[168]
MUC4	OTLT11V1	Strong	Biomarker	[222]
MUC6	OTPVL723	Strong	Altered Expression	[223]
NEIL1	OTHBU5DJ	Strong	Genetic Variation	[224]
NEURL1	OT2C4P70	Strong	Genetic Variation	[225]
NME2	OTCYGLHV	Strong	Altered Expression	[226]
NR2E3	OTO3GBHQ	Strong	Altered Expression	[227]
ONECUT1	OTK1QUQT	Strong	Biomarker	[228]
OPCML	OT93PQ6Y	Strong	Biomarker	[203]
ORM2	OTRJGZP8	Strong	Biomarker	[229]
OSBP	OT7R0OQQ	Strong	Altered Expression	[230]
PAGR1	OTXR5PQ8	Strong	Altered Expression	[59]
PDCD6IP	OTS8T6A7	Strong	Biomarker	[149]
PDHA1	OTGEU8IK	Strong	Biomarker	[231]
PI15	OTPJL6ML	Strong	Biomarker	[232]
PIWIL2	OT1PXQIF	Strong	Altered Expression	[233]
PKD2	OTIXBU8H	Strong	Altered Expression	[234]
PLK3	OT19CT2Z	Strong	Biomarker	[235]
PMAIP1	OTXEE550	Strong	Biomarker	[236]
PODXL	OTPNQXF3	Strong	Altered Expression	[237]
POU2F2	OTPV0J0C	Strong	Biomarker	[116]
PPBP	OT1FHGQS	Strong	Altered Expression	[238]
PPL	OTTM4WDO	Strong	Biomarker	[174]
PPP1R11	OTSHYPPW	Strong	Biomarker	[239]
PPP1R1A	OTGTAGCV	Strong	Biomarker	[240]
PRDX6	OTS8KC8A	Strong	Altered Expression	[241]
PRIMA1	OT9ITT3P	Strong	Biomarker	[242]
PRKACB	OT6RMDCE	Strong	Genetic Variation	[206]
PROX1	OT68R6IO	Strong	Altered Expression	[243]
PRSS2	OTOMVUWL	Strong	Biomarker	[244]
PSG2	OT2EIXAI	Strong	Altered Expression	[36]
PSMA3	OT52M10V	Strong	Biomarker	[245]
PTPN3	OTSLZBVY	Strong	Altered Expression	[246]
RAB7B	OT60A0E9	Strong	Biomarker	[106]
RAD51AP1	OTXM7UTD	Strong	Altered Expression	[247]
RANBP2	OTFG5CVF	Strong	Biomarker	[248]
RASSF1	OTEZIPB7	Strong	Posttranslational Modification	[145]
RHOC	OTOLE1FT	Strong	Biomarker	[202]
RNF2	OTFPLOIN	Strong	Biomarker	[249]
RPLP1	OT7B0SIB	Strong	Biomarker	[250]
RRM2B	OTE8GBUR	Strong	Altered Expression	[227]
S100A2	OTTGHJ1H	Strong	Biomarker	[251]
SAFB	OTGRV2LW	Strong	Altered Expression	[252]
SARNP	OTE0OVK5	Strong	Biomarker	[253]
SCGB2A1	OT9L87U9	Strong	Altered Expression	[254]
SCTR	OTC80IMR	Strong	Biomarker	[255]
SDF4	OTQ7WFYW	Strong	Genetic Variation	[169]
SEMA3B	OTCZCPMS	Strong	Posttranslational Modification	[256]
SEPTIN4	OTD16B30	Strong	Biomarker	[257]
SERPINA7	OTUYVTSU	Strong	Genetic Variation	[125]
SETD1A	OTVVWRIC	Strong	Biomarker	[185]
SFN	OTLJCZ1U	Strong	Biomarker	[258]
SFRP1	OT0U9G41	Strong	Biomarker	[259]
SHC2	OTTWMRNQ	Strong	Biomarker	[260]
SIRT7	OT5M4OT4	Strong	Biomarker	[261]
SNAI2	OT7Y8EJ2	Strong	Biomarker	[29]
SOX17	OT9H4WWE	Strong	Biomarker	[262]
SP110	OTFW6WH7	Strong	Genetic Variation	[181]
SP140	OTQZHFMT	Strong	Genetic Variation	[181]
SPATA20	OTWKX0AZ	Strong	Altered Expression	[263]
SPRR2A	OT62ZU6B	Strong	Biomarker	[73]
SPTB	OT1Q9ABM	Strong	Biomarker	[160]
SPTBN2	OTDMJ75N	Strong	Biomarker	[160]
SRRT	OTMYPSWV	Strong	Altered Expression	[264]
SYCE1L	OTXU44F3	Strong	Biomarker	[18]
TFF2	OTRXB19X	Strong	Genetic Variation	[265]
TICAM2	OTK7GIJ5	Strong	Biomarker	[182]
TLK1	OTICTXI8	Strong	Biomarker	[266]
TMED7	OTONO8E6	Strong	Biomarker	[182]
TMSB10	OTLVZ13T	Strong	Biomarker	[267]
TPD52	OTPKSK43	Strong	Biomarker	[43]
TPM1	OTD73X6R	Strong	Biomarker	[268]
TSPAN1	OTZQPIYK	Strong	Biomarker	[269]
IKBKG	OTNWJWSD	Definitive	Genetic Variation	[270]

References

• [1] Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 May 1;19(5):541-565.
• [2] Carboplatin FDA Label
• [3] ClinicalTrials.gov (NCT04093362) Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements (FOENIX-CCA3). U.S. National Institutes of Health.
• [4] Gemcitabine FDA Label
• [5] FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 214622.
• [6] ClinicalTrials.gov (NCT02989857) Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) (ClarIDHy). U.S. National Institutes of Health.
• [7] Oxaliplatin FDA Label
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] ClinicalTrials.gov (NCT02232633) A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer. U.S. National Institutes of Health.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] ClinicalTrials.gov (NCT03907852) Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer. U.S. National Institutes of Health.
• [14] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [15] ClinicalTrials.gov (NCT02128282) Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma. U.S. National Institutes of Health.
• [16] Increased expression of monoamine oxidase A is associated with epithelial to mesenchymal transition and clinicopathological features in non-small cell lung cancer.Oncol Lett. 2018 Mar;15(3):3245-3251. doi: 10.3892/ol.2017.7683. Epub 2017 Dec 21.
• [17] Genomic spectra of biliary tract cancer.Nat Genet. 2015 Sep;47(9):1003-10. doi: 10.1038/ng.3375. Epub 2015 Aug 10.
• [18] Immunohistochemical Assessment of the Expression of Biliary Transportation Proteins MRP2 and MRP3 in Hepatocellular Carcinoma and in Cholangiocarcinoma.Pathol Oncol Res. 2019 Oct;25(4):1363-1371. doi: 10.1007/s12253-018-0386-8. Epub 2018 Feb 20.
• [19] Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.Cell Death Dis. 2019 Mar 8;10(3):231. doi: 10.1038/s41419-019-1460-1.
• [20] Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study.J Gastroenterol. 2017 Feb;52(2):218-228. doi: 10.1007/s00535-016-1230-0. Epub 2016 Jun 29.
• [21] Role for interleukin-6 in COPD-related pulmonary hypertension.Chest. 2009 Sep;136(3):678-687. doi: 10.1378/chest.08-2420. Epub 2009 Apr 6.
• [22] Genetic factors in the pathogenesis of cholangiocarcinoma.Dig Dis. 2011;29(1):93-7. doi: 10.1159/000324688. Epub 2011 Jun 17.
• [23] A homozygous ABCB4 mutation causing an LPAC syndrome evolves into cholangiocarcinoma.Clin Chim Acta. 2019 Aug;495:598-605. doi: 10.1016/j.cca.2019.06.007. Epub 2019 Jun 7.
• [24] Downregulation of ABCA1 and ABCG1 transporters by simvastatin in cholangiocarcinoma cells.Oncol Lett. 2019 Nov;18(5):5173-5184. doi: 10.3892/ol.2019.10874. Epub 2019 Sep 17.
• [25] Exposure to 1,2-Dichloropropane Upregulates the Expression of Activation-Induced Cytidine Deaminase (AID) in Human Cholangiocytes Co-Cultured With Macrophages.Toxicol Sci. 2019 Mar 1;168(1):137-148. doi: 10.1093/toxsci/kfy280.
• [26] Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth.Cancer Lett. 2017 Feb 1;386:179-188. doi: 10.1016/j.canlet.2016.11.025. Epub 2016 Nov 26.
• [27] Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation. Cancer Lett. 2018 Aug 10;429:1-10.
• [28] Probing the Tumor Suppressor Function of BAP1 in CRISPR-Engineered Human Liver Organoids.Cell Stem Cell. 2019 Jun 6;24(6):927-943.e6. doi: 10.1016/j.stem.2019.04.017. Epub 2019 May 23.
• [29] RNA interference targeting slug increases cholangiocarcinoma cell sensitivity to cisplatin via upregulating PUMA.Int J Mol Sci. 2011 Jan 14;12(1):385-400. doi: 10.3390/ijms12010385.
• [30] Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal.Diagn Pathol. 2019 Jun 21;14(1):62. doi: 10.1186/s13000-019-0843-z.
• [31] miR-21 targets 15-PGDH and promotes cholangiocarcinoma growth. Mol Cancer Ther. 2014 Jun;12(6):890-900.
• [32] The cyclindependent kinase pathway involving CDK1 is a potential therapeutic target for cholangiocarcinoma.Oncol Rep. 2020 Jan;43(1):306-317. doi: 10.3892/or.2019.7405. Epub 2019 Nov 8.
• [33] An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).Pharmacogenet Genomics. 2019 Aug;29(6):123-131. doi: 10.1097/FPC.0000000000000375.
• [34] Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma.Epigenetics. 2016 Nov;11(11):780-790. doi: 10.1080/15592294.2016.1227899. Epub 2016 Sep 3.
• [35] CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263.Cell Death Dis. 2019 Aug 9;10(8):602. doi: 10.1038/s41419-019-1831-7.
• [36] Clinical Significance of Preoperative Serum CEA, CA125, and CA19-9 Levels in Predicting the Resectability of Cholangiocarcinoma.Dis Markers. 2019 Feb 4;2019:6016931. doi: 10.1155/2019/6016931. eCollection 2019.
• [37] CEACAM6 gene expression in intrahepatic cholangiocarcinoma.Br J Cancer. 2006 Aug 21;95(4):532-40. doi: 10.1038/sj.bjc.6603276. Epub 2006 Jul 25.
• [38] 7-Nicotinic Acetylcholine Receptor Promotes Cholangiocarcinoma Progression and Epithelial-Mesenchymal Transition Process.Dig Dis Sci. 2019 Oct;64(10):2843-2853. doi: 10.1007/s10620-019-05609-3. Epub 2019 Apr 4.
• [39] Claudin-18 coupled with EGFR/ERK signaling contributes to the malignant potentials of bile duct cancer.Cancer Lett. 2017 Sep 10;403:66-73. doi: 10.1016/j.canlet.2017.05.033. Epub 2017 Jun 15.
• [40] Overexpression of adenovirus-mediated p27kip1 lacking the Jab1-binding region enhances cytotoxicity and inhibits xenografted human cholangiocarcinoma growth.Anticancer Res. 2009 Jun;29(6):2015-24.
• [41] Downregulation of NAD(P)H:quinone oxidoreductase 1 inhibits proliferation, cell cycle and migration of cholangiocarcinoma cells.Oncol Lett. 2017 Jun;13(6):4540-4548. doi: 10.3892/ol.2017.5951. Epub 2017 Mar 29.
• [42] Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients.Clin Transl Oncol. 2016 Apr;18(4):398-404. doi: 10.1007/s12094-015-1382-z. Epub 2015 Aug 27.
• [43] Identification of TPD52 and DNAJB1 as two novel bile biomarkers for cholangiocarcinoma by iTRAQbased quantitative proteomics analysis.Oncol Rep. 2019 Dec;42(6):2622-2634. doi: 10.3892/or.2019.7387. Epub 2019 Oct 23.
• [44] Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.Pathol Res Pract. 2019 Jul;215(7):152451. doi: 10.1016/j.prp.2019.152451. Epub 2019 May 13.
• [45] Epidermal growth factor-like domain multiple 7 (EGFL7): Expression and possible effect on biliary epithelium growth in cholangiocarcinoma.Eur J Histochem. 2018 Nov 30;62(4):2971. doi: 10.4081/ejh.2018.2971.
• [46] Silencing of LAMC2 Reverses Epithelial-Mesenchymal Transition and Inhibits Angiogenesis in Cholangiocarcinoma via Inactivation of the Epidermal Growth Factor Receptor Signaling Pathway.Am J Pathol. 2019 Aug;189(8):1637-1653. doi: 10.1016/j.ajpath.2019.03.012.
• [47] Cytoplasmic Hu-Antigen R (HuR) Expression is Associated with Poor Survival in Patients with Surgically Resected Cholangiocarcinoma Treated with Adjuvant Gemcitabine-Based Chemotherapy.Ann Surg Oncol. 2018 May;25(5):1202-1210. doi: 10.1245/s10434-018-6392-y. Epub 2018 Feb 28.
• [48] CD133 and epithelial cell adhesion molecule expressions in the cholangiocarcinoma component are prognostic factors for combined hepatocellular cholangiocarcinoma.Hepatol Res. 2020 Feb;50(2):258-267. doi: 10.1111/hepr.13443. Epub 2019 Dec 18.
• [49] Characterization of the erythropoietin/erythropoietin receptor axis in a rat model of liver damage and cholangiocarcinoma development.Histochem Cell Biol. 2013 Mar;139(3):473-85. doi: 10.1007/s00418-012-1037-x. Epub 2012 Oct 4.
• [50] Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.Cancer Chemother Pharmacol. 2019 Apr;83(4):659-671. doi: 10.1007/s00280-019-03768-8. Epub 2019 Jan 18.
• [51] Upregulated FFAR4 correlates with the epithelial-mesenchymal transition and an unfavorable prognosis in human cholangiocarcinoma.Cancer Biomark. 2018;23(3):353-361. doi: 10.3233/CBM-181358.
• [52] FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3/- catenin signaling cascade via FGFR4 activation.Oncotarget. 2016 Mar 22;7(12):13575-86. doi: 10.18632/oncotarget.6185.
• [53] HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma.Hepatology. 2019 Jan;69(1):131-142. doi: 10.1002/hep.30127. Epub 2018 Dec 14.
• [54] Preparation and Characterizations of RSPP050-Loaded Polymeric Micelles Using Poly(ethylene glycol)-b-Poly(-caprolactone) and Poly(ethylene glycol)-b-Poly(D,L-lactide).Chem Pharm Bull (Tokyo). 2017;65(6):530-537. doi: 10.1248/cpb.c16-00871.
• [55] 68Ga-Prostate-Specific Membrane Antigen PET/CT in Cholangiocarcinoma: A Potential Biomarker for Targeted Radioligand Therapy?.Clin Nucl Med. 2019 Jul;44(7):e439-e441. doi: 10.1097/RLU.0000000000002563.
• [56] Fascin Overexpression Promotes Cholangiocarcinoma RBE Cell Proliferation, Migration, and Invasion.Technol Cancer Res Treat. 2016 Apr;15(2):322-33. doi: 10.1177/1533034615580696. Epub 2015 Apr 16.
• [57] FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.J Hepatol. 2013 Dec;59(6):1278-84. doi: 10.1016/j.jhep.2013.08.005. Epub 2013 Aug 16.
• [58] Gadd45 silencing impaired viability and metastatic phenotypes in cholangiocarcinoma cells by modulating the EMT pathway.Oncol Lett. 2018 Mar;15(3):3031-3041. doi: 10.3892/ol.2017.7706. Epub 2017 Dec 28.
• [59] SH2 modified STAT1 induces HLA-I expression and improves IFN- signaling in IFN- resistant HCV replicon cells.PLoS One. 2010 Sep 30;5(9):e13117. doi: 10.1371/journal.pone.0013117.
• [60] Bile acid receptors in the biliary tree: TGR5 in physiology and disease.Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1319-1325. doi: 10.1016/j.bbadis.2017.08.021. Epub 2017 Aug 25.
• [61] Cholangiocarcinoma in Wilson's Disease - a Case Report.J Gastrointestin Liver Dis. 2017 Sep;26(3):305-308. doi: 10.15403/jgld.2014.1121.263.nem.
• [62] Characterization of liver injury, oval cell proliferation and cholangiocarcinogenesis in glutathione S-transferase A3 knockout mice.Carcinogenesis. 2017 Jul 1;38(7):717-727. doi: 10.1093/carcin/bgx048.
• [63] Low levels of pyruvate induced by a positive feedback loop protects cholangiocarcinoma cells from apoptosis.Cell Commun Signal. 2019 Mar 12;17(1):23. doi: 10.1186/s12964-019-0332-8.
• [64] Targeting hexokinase II as a possible therapy for cholangiocarcinoma.Biochem Biophys Res Commun. 2017 Mar 4;484(2):409-415. doi: 10.1016/j.bbrc.2017.01.139. Epub 2017 Jan 25.
• [65] Erythrocyte porphobilinogen deaminase activity and primary liver cancer.J Intern Med. 1995 Mar;237(3):309-13. doi: 10.1111/j.1365-2796.1995.tb01180.x.
• [66] H3 histamine receptor-mediated activation of protein kinase Calpha inhibits the growth of cholangiocarcinoma in vitro and in vivo.Mol Cancer Res. 2009 Oct;7(10):1704-13. doi: 10.1158/1541-7786.MCR-09-0261. Epub 2009 Oct 13.
• [67] Liver-specific knockout of GRP94 in mice disrupts cell adhesion, activates liver progenitor cells, and accelerates liver tumorigenesis.Hepatology. 2014 Mar;59(3):947-57. doi: 10.1002/hep.26711. Epub 2014 Jan 27.
• [68] Aberrant methylation of HTATIP2 and UCHL1 as a predictive biomarker for cholangiocarcinoma.Mol Med Rep. 2018 Mar;17(3):4145-4153. doi: 10.3892/mmr.2017.8319. Epub 2017 Dec 19.
• [69] The Role of 5-HT1A Receptor in Cancer as a New Opportunity in Medicinal Chemistry.Curr Med Chem. 2018;25(27):3214-3227. doi: 10.2174/0929867325666180209141650.
• [70] Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.Invest New Drugs. 2020 Apr;38(2):433-444. doi: 10.1007/s10637-019-00771-x. Epub 2019 Apr 26.
• [71] Akirin2 is modulated by miR-490-3p and facilitates angiogenesis in cholangiocarcinoma through the IL-6/STAT3/VEGFA signaling pathway.Cell Death Dis. 2019 Mar 18;10(4):262. doi: 10.1038/s41419-019-1506-4.
• [72] The clinical significance and biological function of interferon regulatory factor 1 in cholangiocarcinoma.Biomed Pharmacother. 2018 Jan;97:771-777. doi: 10.1016/j.biopha.2017.10.096. Epub 2017 Nov 6.
• [73] Breast tumor kinase/protein tyrosine kinase 6 (Brk/PTK6) activity in normal and neoplastic biliary epithelia.J Hepatol. 2015 Aug;63(2):399-407. doi: 10.1016/j.jhep.2015.02.047. Epub 2015 Mar 12.
• [74] MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment.Cell Death Dis. 2019 Feb 11;10(2):120. doi: 10.1038/s41419-019-1389-4.
• [75] YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.Int J Mol Sci. 2019 Feb 1;20(3):638. doi: 10.3390/ijms20030638.
• [76] Upregulated LASP-1 correlates with a malignant phenotype and its potential therapeutic role in human cholangiocarcinoma.Tumour Biol. 2016 Jun;37(6):8305-15. doi: 10.1007/s13277-015-4704-4. Epub 2016 Jan 4.
• [77] YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity.Mol Cancer Res. 2018 Oct;16(10):1556-1567. doi: 10.1158/1541-7786.MCR-18-0158. Epub 2018 Jun 14.
• [78] The interaction of LOXL2 with GATA6 induces VEGFA expression and angiogenesis in cholangiocarcinoma.Int J Oncol. 2019 Sep;55(3):657-670. doi: 10.3892/ijo.2019.4837. Epub 2019 Jul 15.
• [79] Genetic detection for micrometastasis in lymph node of biliary tract carcinoma.Clin Cancer Res. 2000 Jun;6(6):2326-32.
• [80] Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion.World J Gastroenterol. 2007 Mar 14;13(10):1561-8. doi: 10.3748/wjg.v13.i10.1561.
• [81] MAP3K1 rs889312 genotypes influence survival outcomes of Chinese gastric cancer patients who received adjuvant chemotherapy based on platinum and fluorouracil regimes.Onco Targets Ther. 2019 Aug 22;12:6843-6855. doi: 10.2147/OTT.S205438. eCollection 2019.
• [82] Myristoylated alanine-rich C kinase substrate phosphorylation promotes cholangiocarcinoma cell migration and metastasis via the protein kinase C-dependent pathway.Cancer Sci. 2010 Mar;101(3):658-65. doi: 10.1111/j.1349-7006.2009.01427.x. Epub 2009 Nov 7.
• [83] Transcriptional induction of minichromosome maintenance protein 7 (Mcm7) in human cholangiocarcinoma cells treated with Clonorchis sinensis excretory-secretory products.Mol Biochem Parasitol. 2010 Sep;173(1):10-6. doi: 10.1016/j.molbiopara.2010.03.005. Epub 2010 Mar 15.
• [84] Blocking of methionine aminopeptidase-2 by TNP-470 induces apoptosis and increases chemosensitivity of cholangiocarcinoma.J Cancer Res Ther. 2019 Jan-Mar;15(1):148-152. doi: 10.4103/jcrt.JCRT_250_17.
• [85] Prostaglandin E2 receptor EP1 phosphorylate CREB and mediates MMP2 expression in human cholangiocarcinoma cells.Mol Cell Biochem. 2013 Jun;378(1-2):195-203. doi: 10.1007/s11010-013-1610-1. Epub 2013 Mar 15.
• [86] Liver myofibroblasts of murine origins express mesothelin: Identification of novel rat mesothelin splice variants.PLoS One. 2017 Sep 12;12(9):e0184499. doi: 10.1371/journal.pone.0184499. eCollection 2017.
• [87] Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis.Pathol Oncol Res. 2020 Apr;26(2):791-800. doi: 10.1007/s12253-019-00626-z. Epub 2019 Feb 28.
• [88] Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholangitis.Oncotarget. 2018 Apr 3;9(25):17430-17442. doi: 10.18632/oncotarget.24732. eCollection 2018 Apr 3.
• [89] MYH rs3219476 and rs3219472 polymorphisms and risk of cholangiocarcinoma.Mol Med Rep. 2013 Jan;7(1):347-51. doi: 10.3892/mmr.2012.1175. Epub 2012 Nov 8.
• [90] Nek2 siRNA therapy using a portal venous port-catheter system for liver metastasis in pancreatic cancer.Cancer Sci. 2016 Sep;107(9):1315-20. doi: 10.1111/cas.12993. Epub 2016 Aug 12.
• [91] Establishment and characterization of chromosomal aberrations in human cholangiocarcinoma cell lines by cross-species color banding.Genes Chromosomes Cancer. 2001 Jan;30(1):48-56. doi: 10.1002/1098-2264(2000)9999:9999<::aid-gcc1053>3.0.co;2-p.
• [92] Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice.Cancer Res. 2006 Jul 1;66(13):6622-7. doi: 10.1158/0008-5472.CAN-05-4609.
• [93] Allicin Inhibits Proliferation and Invasion in Vitro and in Vivo via SHP-1-Mediated STAT3 Signaling in Cholangiocarcinoma.Cell Physiol Biochem. 2018;47(2):641-653. doi: 10.1159/000490019. Epub 2018 May 22.
• [94] The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.PLoS One. 2019 Jan 24;14(1):e0210077. doi: 10.1371/journal.pone.0210077. eCollection 2019.
• [95] Salinomycin enhances doxorubicin sensitivity through reversing the epithelial-mesenchymal transition of cholangiocarcinoma cells by regulating ARK5.Braz J Med Biol Res. 2017 Aug 17;50(10):e6147. doi: 10.1590/1414-431X20176147.
• [96] PBRM1 loss is a late event during the development of cholangiocarcinoma.Histopathology. 2017 Sep;71(3):375-382. doi: 10.1111/his.13234. Epub 2017 Jun 22.
• [97] Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances.Hepatology. 2019 Apr;69(4):1803-1815. doi: 10.1002/hep.30289. Epub 2019 Mar 25.
• [98] Bile duct expression of pancreatic and duodenal homeobox 1 in perihilar cholangiocarcinogenesis.Histopathology. 2012 Aug;61(2):266-76. doi: 10.1111/j.1365-2559.2012.04218.x. Epub 2012 May 17.
• [99] Prohibitin 1 suppresses liver cancer tumorigenesis in mice and human hepatocellular and cholangiocarcinoma cells.Hepatology. 2017 Apr;65(4):1249-1266. doi: 10.1002/hep.28964. Epub 2017 Jan 31.
• [100] Leptin stimulates the epithelialmesenchymal transition and proangiogenic capability of cholangiocarcinoma cells through the miR?22/PKM2 axis.Int J Oncol. 2019 Jul;55(1):298-308. doi: 10.3892/ijo.2019.4807. Epub 2019 May 21.
• [101] Secreted cyclophilin A mediates G1/S phase transition of cholangiocarcinoma cells via CD147/ERK1/2 pathway.Tumour Biol. 2015 Feb;36(2):849-59. doi: 10.1007/s13277-014-2691-5. Epub 2014 Oct 10.
• [102] Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma.Liver Int. 2018 Dec;38(12):2248-2259. doi: 10.1111/liv.13887. Epub 2018 Jun 12.
• [103] Correlation of aPKC-iota and E-cadherin expression with invasion and prognosis of cholangiocarcinoma.Hepatobiliary Pancreat Dis Int. 2008 Feb;7(1):70-5.
• [104] Combination of Kras activation and PTEN deletion contributes to murine hepatopancreatic ductal malignancy.Cancer Lett. 2018 May 1;421:161-169. doi: 10.1016/j.canlet.2018.02.017. Epub 2018 Feb 13.
• [105] Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis.QJM. 2019 Jun 1;112(6):421-427. doi: 10.1093/qjmed/hcz039.
• [106] Disruption of endocytic trafficking protein Rab7 impairs invasiveness of cholangiocarcinoma cells.Cancer Biomark. 2017 Sep 7;20(3):255-266. doi: 10.3233/CBM-170030.
• [107] Oncogenic retinoic acid receptor knockdown reverses multi-drug resistance of human colorectal cancer via Wnt/-catenin pathway.Cell Cycle. 2017 Apr 3;16(7):685-692. doi: 10.1080/15384101.2017.1295180. Epub 2017 Mar 8.
• [108] Exome sequencing of liver fluke-associated cholangiocarcinoma.Nat Genet. 2012 May 6;44(6):690-3. doi: 10.1038/ng.2273.
• [109] The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.Nat Commun. 2019 Aug 9;10(1):3604. doi: 10.1038/s41467-019-11496-z.
• [110] 67 laminin receptor promotes the malignant potential of tumour cells up-regulating lysyl oxidase-like 2 expression in cholangiocarcinoma.Dig Liver Dis. 2014 Aug;46(8):750-7. doi: 10.1016/j.dld.2014.03.017. Epub 2014 May 1.
• [111] Conjugated Bile Acids Promote Invasive Growth of Esophageal Adenocarcinoma Cells and Cancer Stem Cell Expansion via Sphingosine 1-Phosphate Receptor 2-Mediated Yes-Associated Protein Activation.Am J Pathol. 2018 Sep;188(9):2042-2058. doi: 10.1016/j.ajpath.2018.05.015. Epub 2018 Jun 30.
• [112] Tumoral heterogeneity of hepatic cholangiocarcinomas revealed by MALDI imaging mass spectrometry.Proteomics. 2014 Apr;14(7-8):965-72. doi: 10.1002/pmic.201300463.
• [113] LncRNA LINC01061 sponges miR-612 to regulate the oncogenic role of SEMA4D in cholangiocarcinoma.Biochem Biophys Res Commun. 2019 May 28;513(2):465-471. doi: 10.1016/j.bbrc.2019.03.125. Epub 2019 Apr 6.
• [114] Upregulation of transferrin receptor-1 induces cholangiocarcinoma progression via induction of labile iron pool.Tumour Biol. 2017 Jul;39(7):1010428317717655. doi: 10.1177/1010428317717655.
• [115] Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy. Hepatology. 2019 Apr 10.
• [116] Network analyses-based identification of circular ribonucleic acid-related pathways in intrahepatic cholangiocarcinoma.Tumour Biol. 2018 Sep;40(9):1010428318795761. doi: 10.1177/1010428318795761.
• [117] SVCT-2 determines the sensitivity to ascorbate-induced cell death in cholangiocarcinoma cell lines and patient derived xenografts.Cancer Lett. 2017 Jul 10;398:1-11. doi: 10.1016/j.canlet.2017.03.039. Epub 2017 Apr 4.
• [118] Overexpression of ATA1/SLC38A1 predicts future recurrence and death in Chinese patients with hilar cholangiocarcinoma.J Surg Res. 2011 Dec;171(2):663-8. doi: 10.1016/j.jss.2010.03.049. Epub 2010 Apr 18.
• [119] Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment.Tumour Biol. 2017 Mar;39(3):1010428317694545. doi: 10.1177/1010428317694545.
• [120] Sodium iodide symporter is expressed at the preneoplastic stages of liver carcinogenesis and in human cholangiocarcinoma.Gastroenterology. 2007 Apr;132(4):1495-503. doi: 10.1053/j.gastro.2007.01.044. Epub 2007 Jan 26.
• [121] Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition.Gastroenterology. 1995 Jun;108(6):1908-16. doi: 10.1016/0016-5085(95)90157-4.
• [122] TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors.Oncotarget. 2016 Nov 15;7(46):75441-75456. doi: 10.18632/oncotarget.12254.
• [123] Photoimmunotherapy targeting biliary-pancreatic cancer with humanized anti-TROP2 antibody.Cancer Med. 2019 Dec;8(18):7781-7792. doi: 10.1002/cam4.2658. Epub 2019 Nov 1.
• [124] Estrogen is increased in male cholangiocarcinoma patients' serum and stimulates invasion in cholangiocarcinoma cell lines in vitro.J Cancer Res Clin Oncol. 2012 Aug;138(8):1311-20. doi: 10.1007/s00432-012-1207-1. Epub 2012 Apr 3.
• [125] Epithelial Transforming Growth Factor- Signaling Does Not Contribute to Liver Fibrosis but Protects Mice From Cholangiocarcinoma.Gastroenterology. 2016 Mar;150(3):720-33. doi: 10.1053/j.gastro.2015.11.039. Epub 2015 Nov 26.
• [126] Differential gene expression profiling of cultured neu-transformed versus spontaneously-transformed rat cholangiocytes and of corresponding cholangiocarcinomas.Exp Mol Pathol. 2010 Dec;89(3):227-35. doi: 10.1016/j.yexmp.2010.08.007. Epub 2010 Sep 9.
• [127] Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.J Hepatol. 2019 Oct;71(4):753-762. doi: 10.1016/j.jhep.2019.05.026. Epub 2019 Jun 11.
• [128] Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth.Cancer Res. 2008 Nov 15;68(22):9184-93. doi: 10.1158/0008-5472.CAN-08-2133.
• [129] Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.Gene. 2019 May 25;698:50-60. doi: 10.1016/j.gene.2019.02.044. Epub 2019 Feb 27.
• [130] Polymorphisms of estrogen receptors and risk of biliary tract cancers and gallstones: a population-based study in Shanghai, China.Carcinogenesis. 2010 May;31(5):842-6. doi: 10.1093/carcin/bgq038. Epub 2010 Feb 19.
• [131] Orotate phosphoribosyltransferase as a predictor of benefit from S-1 adjuvant chemotherapy for cholangiocarcinoma patients.J Gastroenterol Hepatol. 2019 Jun;34(6):1108-1115. doi: 10.1111/jgh.14477. Epub 2018 Oct 19.
• [132] Ubiquitin-specific protease 14 expression associated with intrahepatic cholangiocarcinoma cell differentiation.Asian Pac J Cancer Prev. 2011;12(3):775-9.
• [133] Liver transplantation and combined hepatocellular-cholangiocarcinoma: Feasibility and outcomes.Dig Liver Dis. 2017 May;49(5):467-470. doi: 10.1016/j.dld.2017.01.166. Epub 2017 Feb 6.
• [134] A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes.Hepatology. 2012 Jan;55(1):173-83. doi: 10.1002/hep.24691.
• [135] Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma.Sci Rep. 2019 Mar 13;9(1):4338. doi: 10.1038/s41598-019-40487-9.
• [136] Mutational analysis of the p53 and K-ras genes and allelotype study of the Rb-1 gene for investigating the pathogenesis of combined hapatocellular-cholangiocellular carcinomas.Jpn J Cancer Res. 1996 Oct;87(10):1056-62. doi: 10.1111/j.1349-7006.1996.tb03110.x.
• [137] Omega-3 Polyunsaturated Fatty Acids Upregulate 15-PGDH Expression in Cholangiocarcinoma Cells by Inhibiting miR-26a/b Expression.Cancer Res. 2015 Apr 1;75(7):1388-98. doi: 10.1158/0008-5472.CAN-14-2561. Epub 2015 Feb 17.
• [138] Inflammatory cytokines suppress arylamine N-acetyltransferase 1 in cholangiocarcinoma cells.World J Gastroenterol. 2007 Dec 14;13(46):6219-25. doi: 10.3748/wjg.v13.i46.6219.
• [139] miR-34a-dependent overexpression of Per1 decreases cholangiocarcinoma growth.J Hepatol. 2016 Jun;64(6):1295-304. doi: 10.1016/j.jhep.2016.02.024. Epub 2016 Feb 24.
• [140] Differential down-regulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer.Cancer Res. 1997 Jul 15;57(14):2979-85.
• [141] High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.Cancer Med. 2018 Nov;7(11):5525-5533. doi: 10.1002/cam4.1833. Epub 2018 Oct 24.
• [142] Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer.Gastroenterology. 2018 Aug;155(2):557-571.e14. doi: 10.1053/j.gastro.2018.04.032. Epub 2018 May 5.
• [143] Imbalanced expression pattern of steroid receptor coactivator-1 and -3 in liver cancer compared with normal liver: An immunohistochemical study with tissue microarray.Oncol Lett. 2018 Nov;16(5):6339-6348. doi: 10.3892/ol.2018.9443. Epub 2018 Sep 17.
• [144] Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas.Gastroenterology. 2006 Nov;131(5):1418-30. doi: 10.1053/j.gastro.2006.08.034. Epub 2006 Aug 18.
• [145] Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma.Mod Pathol. 2005 Mar;18(3):412-20. doi: 10.1038/modpathol.3800287.
• [146] NRSF/REST levels are decreased in cholangiocellular carcinoma but not hepatocellular carcinoma compared with normal liver tissues: A tissue microarray study.Oncol Lett. 2018 May;15(5):6592-6598. doi: 10.3892/ol.2018.8169. Epub 2018 Mar 5.
• [147] Targeted drug regulation on methylation of p53-BAX mitochondrial apoptosis pathway affects the growth of cholangiocarcinoma cells.J Int Med Res. 2012;40(1):67-75. doi: 10.1177/147323001204000107.
• [148] Cholesterol metabolism gene polymorphisms and the risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China.Carcinogenesis. 2011 Jan;32(1):58-62. doi: 10.1093/carcin/bgq194. Epub 2010 Nov 9.
• [149] Outcome and Genetic Factors in IgG4-Associated Autoimmune Pancreatitis and Cholangitis: A Single Center Experience.Gastroenterol Res Pract. 2017;2017:6126707. doi: 10.1155/2017/6126707. Epub 2017 Mar 2.
• [150] Genetics of primary sclerosing cholangitis and pathophysiological implications.Nat Rev Gastroenterol Hepatol. 2017 May;14(5):279-295. doi: 10.1038/nrgastro.2016.154. Epub 2017 Mar 15.
• [151] LncRNA AFAP1-AS1 promotes growth and metastasis of cholangiocarcinoma cells.Oncotarget. 2017 Apr 6;8(35):58394-58404. doi: 10.18632/oncotarget.16880. eCollection 2017 Aug 29.
• [152] Differential expression of anterior gradient protein 3 in intrahepatic cholangiocarcinoma and hepatocellular carcinoma.Exp Mol Pathol. 2014 Jun;96(3):375-81. doi: 10.1016/j.yexmp.2014.04.002. Epub 2014 Apr 18.
• [153] ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients.Clin Cancer Res. 2016 Aug 15;22(16):4225-35. doi: 10.1158/1078-0432.CCR-15-1800. Epub 2016 Apr 13.
• [154] miR-122-5p Inhibits the Proliferation, Invasion and Growth of Bile Duct Carcinoma Cells by Targeting ALDOA.Cell Physiol Biochem. 2018;48(6):2596-2606. doi: 10.1159/000492702. Epub 2018 Aug 17.
• [155] Differential membrane proteomics using 18O-labeling to identify biomarkers for cholangiocarcinoma.J Proteome Res. 2008 Nov;7(11):4670-7. doi: 10.1021/pr800215n. Epub 2008 Oct 8.
• [156] Role of AP-2 and MAPK7 in the regulation of autocrine TGF-/miR-200b signals to maintain epithelial-mesenchymal transition in cholangiocarcinoma.J Hematol Oncol. 2017 Oct 30;10(1):170. doi: 10.1186/s13045-017-0528-6.
• [157] Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma.Carcinogenesis. 2020 Jul 10;41(6):734-742. doi: 10.1093/carcin/bgz179.
• [158] Differences in corpus callosum injury between cerebral concussion and diffuse axonal injury.Medicine (Baltimore). 2019 Oct;98(41):e17467. doi: 10.1097/MD.0000000000017467.
• [159] Long non-coding RNA NNT-AS1 functions as an oncogenic gene through modulating miR-485/BCL9 in cholangiocarcinoma.Cancer Manag Res. 2019 Aug 15;11:7739-7749. doi: 10.2147/CMAR.S207801. eCollection 2019.
• [160] Utilization of spectrins I and III in diagnosis of hepatocellular carcinoma.Ann Diagn Pathol. 2019 Apr;39:86-91. doi: 10.1016/j.anndiagpath.2019.02.009. Epub 2019 Feb 15.
• [161] Anticancer activity of synthetic ()-kusunokinin and its derivative ()-bursehernin on human cancer cell lines.Biomed Pharmacother. 2019 Sep;117:109115. doi: 10.1016/j.biopha.2019.109115. Epub 2019 Jun 17.
• [162] Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model.Clin Cancer Res. 2019 Oct 15;25(20):6148-6159. doi: 10.1158/1078-0432.CCR-19-1157. Epub 2019 Jul 23.
• [163] Dicer promotes tumorigenesis by translocating to nucleus to promote SFRP1 promoter methylation in cholangiocarcinoma cells.Cell Death Dis. 2017 Feb 23;8(2):e2628. doi: 10.1038/cddis.2017.57.
• [164] High expression of CCDC25 in cholangiocarcinoma tissue samples.Oncol Lett. 2017 Aug;14(2):2566-2572. doi: 10.3892/ol.2017.6446. Epub 2017 Jun 21.
• [165] Curcumol Exerts Anticancer Effect in Cholangiocarcinoma Cells via Down-Regulating CDKL3.Front Physiol. 2018 Mar 20;9:234. doi: 10.3389/fphys.2018.00234. eCollection 2018.
• [166] The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancers.Int J Cancer. 2015 Feb 15;136(4):844-53. doi: 10.1002/ijc.29039. Epub 2014 Jun 28.
• [167] Prognosis and modulation mechanisms of COMMD6 in human tumours based on expression profiling and comprehensive bioinformatics analysis.Br J Cancer. 2019 Oct;121(8):699-709. doi: 10.1038/s41416-019-0571-x. Epub 2019 Sep 16.
• [168] Expression of phosphorylated ERK1/2 and homeodomain protein CDX2 in cholangiocarcinoma.J Cancer Res Clin Oncol. 2006 Dec;132(12):805-10. doi: 10.1007/s00432-006-0129-1. Epub 2006 Jun 23.
• [169] Calcium-binding protein S100P is a novel diagnostic marker of cholangiocarcinoma.Cancer Sci. 2011 Jan;102(1):150-6. doi: 10.1111/j.1349-7006.2010.01757.x. Epub 2010 Oct 13.
• [170] Clinical significance of chromodomain helicase/ATPase DNA binding protein 1-like and human mutL homolog 1 gene expression in cholangiocarcinoma.Oncol Lett. 2018 Sep;16(3):2989-2994. doi: 10.3892/ol.2018.9043. Epub 2018 Jun 28.
• [171] Apoptosis-related protein-1 acts as a tumor suppressor in cholangiocarcinoma cells by inducing cell cycle arrest via downregulation of cyclin-dependent kinase subunits.Oncol Rep. 2016 Feb;35(2):809-16. doi: 10.3892/or.2015.4422. Epub 2015 Nov 16.
• [172] Oncogenic potential of cyclin kinase subunit-2 in cholangiocarcinoma.Liver Int. 2013 Jan;33(1):137-48. doi: 10.1111/liv.12014. Epub 2012 Nov 1.
• [173] Downregulation of COPB2 by RNAi inhibits growth of human cholangiocellular carcinoma cells.Eur Rev Med Pharmacol Sci. 2018 Feb;22(4):985-992. doi: 10.26355/eurrev_201802_14380.
• [174] Anchored multiplex PCR for targeted next-generation sequencing.Nat Med. 2014 Dec;20(12):1479-84. doi: 10.1038/nm.3729. Epub 2014 Nov 10.
• [175] Cyclic adenosine monophosphate-regulated transcriptional co-activator 3 polymorphism in Chinese patients with acute coronary syndrome.Medicine (Baltimore). 2018 Jul;97(27):e11382. doi: 10.1097/MD.0000000000011382.
• [176] Overexpressions of CK2 and XIAP are associated with poor prognosis of patients with cholangiocarcinoma.Pathol Oncol Res. 2014 Jan;20(1):73-9. doi: 10.1007/s12253-013-9660-y. Epub 2013 Jul 5.
• [177] Cul4B is a novel prognostic marker in cholangiocarcinoma.Oncol Lett. 2017 Aug;14(2):1265-1274. doi: 10.3892/ol.2017.6297. Epub 2017 Jun 1.
• [178] Dihydroartemisinin induces apoptosis and autophagy-dependent cell death in cholangiocarcinoma through a DAPK1-BECLIN1 pathway.Mol Carcinog. 2018 Dec;57(12):1735-1750. doi: 10.1002/mc.22893. Epub 2018 Sep 5.
• [179] Novel centrosome protein, TCC52, is a cancer-testis antigen.Cancer Sci. 2008 Nov;99(11):2274-9. doi: 10.1111/j.1349-7006.2008.00937.x. Epub 2008 Oct 14.
• [180] Comparison of short- and long-term outcomes between anatomical subtypes of resected biliary tract cancer in a Western high-volume center.HPB (Oxford). 2020 Mar;22(3):405-414. doi: 10.1016/j.hpb.2019.07.011. Epub 2019 Sep 4.
• [181] Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis.Gut. 2018 Aug;67(8):1517-1524. doi: 10.1136/gutjnl-2016-313598. Epub 2017 Aug 4.
• [182] Phosphorylation of P27 by AKT is required for inhibition of cell cycle progression in cholangiocarcinoma.Dig Liver Dis. 2018 May;50(5):501-506. doi: 10.1016/j.dld.2017.12.021. Epub 2018 Jan 4.
• [183] Aberrant promoter CpG islands methylation of tumor suppressor genes in cholangiocarcinoma.Oncol Res. 2008;17(4):151-7. doi: 10.3727/096504008785114110.
• [184] Decrease of deleted in malignant brain tumour-1 (DMBT-1) expression is a crucial late event in intrahepatic cholangiocarcinoma.Histopathology. 2003 Oct;43(4):340-6. doi: 10.1046/j.1365-2559.2003.01719.x.
• [185] Upregulation of DPY30 promotes cell proliferation and predicts a poor prognosis in cholangiocarcinoma.Biomed Pharmacother. 2020 Mar;123:109766. doi: 10.1016/j.biopha.2019.109766. Epub 2019 Dec 14.
• [186] The tumor-associated antigen, RCAS1, can be expressed in immune-mediated diseases as well as in carcinomas of biliary tract.J Hepatol. 2002 Jun;36(6):786-92. doi: 10.1016/s0168-8278(02)00066-1.
• [187] Overexpression of ECM1 contributes to migration and invasion in cholangiocarcinoma cell.Neoplasma. 2012;59(4):409-15. doi: 10.4149/neo_2012_053.
• [188] Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.Science. 2014 May 9;344(6184):641-5. doi: 10.1126/science.1251102.
• [189] Expression of endoplasmic reticulum oxidoreductase 1- in cholangiocarcinoma tissues and its effects on the proliferation and migration of cholangiocarcinoma cells.Cancer Manag Res. 2019 Jul 19;11:6727-6739. doi: 10.2147/CMAR.S188746. eCollection 2019.
• [190] Increased ETV4 expression correlates with estrogen-enhanced proliferation and invasiveness of cholangiocarcinoma cells.Cancer Cell Int. 2018 Feb 20;18:25. doi: 10.1186/s12935-018-0525-z. eCollection 2018.
• [191] Tamoxifen (TMX)/Fas induced growth inhibition of human cholangiocarcinoma (HCC) by gamma interferon (IFN-gamma).Ann Surg. 2002 Jun;235(6):872-8. doi: 10.1097/00000658-200206000-00016.
• [192] Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study.J Crohns Colitis. 2019 Dec 10;13(12):1492-1500. doi: 10.1093/ecco-jcc/jjz094.
• [193] Long noncoding RNA DANCR regulates proliferation and migration by epigenetically silencing FBP1 in tumorigenesis of cholangiocarcinoma.Cell Death Dis. 2019 Aug 5;10(8):585. doi: 10.1038/s41419-019-1810-z.
• [194] Terminal fucose mediates progression of human cholangiocarcinoma through EGF/EGFR activation and the Akt/Erk signaling pathway.Sci Rep. 2019 Nov 21;9(1):17266. doi: 10.1038/s41598-019-53601-8.
• [195] Methylation-Mediated Silencing of GATA5 Gene Suppresses Cholangiocarcinoma Cell Proliferation and Metastasis.Transl Oncol. 2018 Jun;11(3):585-592. doi: 10.1016/j.tranon.2018.01.023. Epub 2018 Mar 13.
• [196] Expression of augmenter of liver regeneration (ALR) in human liver cirrhosis and carcinoma.Histopathology. 2005 Jul;47(1):57-66. doi: 10.1111/j.1365-2559.2005.02172.x.
• [197] GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection.J Hepatol. 2005 Sep;43(3):388-93. doi: 10.1016/j.jhep.2005.03.020.
• [198] Glycine N-methyltransferase is a favorable prognostic marker for human cholangiocarcinoma.J Gastroenterol Hepatol. 2008 Sep;23(9):1384-9. doi: 10.1111/j.1440-1746.2008.05488.x. Epub 2008 Jul 8.
• [199] GSTM3 and GSTP1: novel players driving tumor progression in cervical cancer.Oncotarget. 2018 Apr 24;9(31):21696-21714. doi: 10.18632/oncotarget.24796. eCollection 2018 Apr 24.
• [200] Two variants on T2DM susceptible gene HHEX are associated with CRC risk in a Chinese population.Oncotarget. 2016 May 17;7(20):29770-9. doi: 10.18632/oncotarget.8865.
• [201] Detection of IGF2BP3, HOXB7, and NEK2 mRNA expression in brush cytology specimens as a new diagnostic tool in patients with biliary strictures.PLoS One. 2012;7(8):e42141. doi: 10.1371/journal.pone.0042141. Epub 2012 Aug 7.
• [202] HOXD10 acts as a tumor-suppressive factor via inhibition of the RHOC/AKT/MAPK pathway in human cholangiocellular carcinoma.Oncol Rep. 2015 Oct;34(4):1681-91. doi: 10.3892/or.2015.4194. Epub 2015 Aug 10.
• [203] Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases.Clin Epigenetics. 2019 Mar 4;11(1):39. doi: 10.1186/s13148-019-0634-0.
• [204] Lentivirus-mediated overexpression of HSDL2 suppresses cell proliferation and induces apoptosis in cholangiocarcinoma.Onco Targets Ther. 2018 Oct 17;11:7133-7142. doi: 10.2147/OTT.S176410. eCollection 2018.
• [205] ID3 Promotes Stem Cell Features and Predicts Chemotherapeutic Response of Intrahepatic Cholangiocarcinoma.Hepatology. 2019 May;69(5):1995-2012. doi: 10.1002/hep.30404. Epub 2019 Mar 8.
• [206] Targeting cholangiocarcinoma.Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1454-1460. doi: 10.1016/j.bbadis.2017.08.027. Epub 2017 Aug 24.
• [207] Interferon -inducible protein 27 is an oncogene and highly expressed in cholangiocarcinoma patients with poor survival.Cancer Manag Res. 2019 Feb 28;11:1893-1905. doi: 10.2147/CMAR.S196485. eCollection 2019.
• [208] Aberrant DNA methylation of integrin alpha4: a potential novel role for metastasis of cholangiocarcinoma.J Cancer Res Clin Oncol. 2010 Feb;136(2):187-94. doi: 10.1007/s00432-009-0646-9. Epub 2009 Aug 5.
• [209] The expression of arginase-1, keratin (K) 8 and K18 in combined hepatocellular-cholangiocarcinoma, subtypes with stem-cell features, intermediate-cell type.J Clin Pathol. 2016 Oct;69(10):846-51. doi: 10.1136/jclinpath-2015-203491. Epub 2016 Mar 11.
• [210] A recurrent ITGA9 missense mutation in human fetuses with severe chylothorax: possible correlation with poor response to fetal therapy.Prenat Diagn. 2008 Nov;28(11):1057-63. doi: 10.1002/pd.2130.
• [211] Inhibition of KLHL21 prevents cholangiocarcinoma progression through regulating cell proliferation and motility, arresting cell cycle and reducing Erk activation.Biochem Biophys Res Commun. 2018 May 15;499(3):433-440. doi: 10.1016/j.bbrc.2018.03.152. Epub 2018 Mar 31.
• [212] Overexpression of karyopherin-2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins.Oncotarget. 2017 Jun 27;8(26):42159-42172. doi: 10.18632/oncotarget.15020.
• [213] Histogenesis of primary liver carcinomas: strengths and weaknesses of cytokeratin profile and albumin mRNA detection.Hum Pathol. 1996 Jun;27(6):599-604. doi: 10.1016/s0046-8177(96)90169-0.
• [214] High expression of L-type amino acid transporter 1 as a prognostic marker in bile duct adenocarcinomas.Cancer Med. 2014 Oct;3(5):1246-55. doi: 10.1002/cam4.272. Epub 2014 Jun 2.
• [215] MACC1 promotes angiogenesis in cholangiocarcinoma by upregulating VEGFA.Onco Targets Ther. 2019 Mar 8;12:1893-1903. doi: 10.2147/OTT.S197319. eCollection 2019.
• [216] p38delta/MAPK13 as a diagnostic marker for cholangiocarcinoma and its involvement in cell motility and invasion.Int J Cancer. 2010 May 15;126(10):2353-61. doi: 10.1002/ijc.24944.
• [217] Cholangiocarcinomas associated with long-term inflammation express the activation-induced cytidine deaminase and germinal center-associated nuclear protein involved in immunoglobulin V-region diversification.Int J Oncol. 2009 Aug;35(2):287-95.
• [218] YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors.Hepatology. 2015 Nov;62(5):1497-510. doi: 10.1002/hep.27992. Epub 2015 Aug 25.
• [219] MORC2 promotes cell growth and metastasis in human cholangiocarcinoma and is negatively regulated by miR-186-5p.Aging (Albany NY). 2019 Jun 9;11(11):3639-3649. doi: 10.18632/aging.102003.
• [220] PGC1 promotes cholangiocarcinoma metastasis by upregulating PDHA1 and MPC1 expression to reverse the Warburg effect.Cell Death Dis. 2018 May 1;9(5):466. doi: 10.1038/s41419-018-0494-0.
• [221] The evaluation of MSX2 mRNA expression level in biliary brush cytological specimens.Anticancer Res. 2011 Mar;31(3):1011-7.
• [222] Prognostic value of MUC4 for mass-forming intrahepatic cholangiocarcinoma after hepatectomy.Oncol Rep. 2009 Jan;21(1):49-56.
• [223] The MUC6 secretory mucin gene is expressed in a wide variety of epithelial tissues.J Pathol. 1998 Dec;186(4):398-405. doi: 10.1002/(SICI)1096-9896(199812)186:4<398::AID-PATH192>3.0.CO;2-X.
• [224] Catalytically impaired hMYH and NEIL1 mutant proteins identified in patients with primary sclerosing cholangitis and cholangiocarcinoma.Carcinogenesis. 2009 Jul;30(7):1147-54. doi: 10.1093/carcin/bgp118. Epub 2009 May 14.
• [225] HER2/neu-directed therapy for biliary tract cancer.J Hematol Oncol. 2015 May 29;8:58. doi: 10.1186/s13045-015-0155-z.
• [226] Recruited metastasis suppressor NM23-H2 attenuates expression and activity of peroxisome proliferator-activated receptor (PPAR) in human cholangiocarcinoma.Dig Liver Dis. 2015 Jan;47(1):62-7. doi: 10.1016/j.dld.2014.09.002. Epub 2014 Sep 29.
• [227] Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.J Hepatobiliary Pancreat Sci. 2011 Sep;18(5):700-11. doi: 10.1007/s00534-011-0376-7.
• [228] Hepatocyte nuclear factor 6 inhibits the growth and metastasis of cholangiocarcinoma cells by regulating miR-122.J Cancer Res Clin Oncol. 2016 May;142(5):969-80. doi: 10.1007/s00432-016-2121-8. Epub 2016 Jan 29.
• [229] Plasma orosomucoid 2 as a potential risk marker of cholangiocarcinoma.Cancer Biomark. 2017;18(1):27-34. doi: 10.3233/CBM-160670.
• [230] Expression of oxysterol binding protein isoforms in opisthorchiasis-associated cholangiocarcinoma: a potential molecular marker for tumor metastasis.Parasitol Int. 2012 Mar;61(1):136-9. doi: 10.1016/j.parint.2011.07.003. Epub 2011 Jul 8.
• [231] SIRT3 elicited an anti-Warburg effect through HIF1/PDK1/PDHA1 to inhibit cholangiocarcinoma tumorigenesis.Cancer Med. 2019 May;8(5):2380-2391. doi: 10.1002/cam4.2089. Epub 2019 Apr 16.
• [232] Peptidase inhibitor 15 as a novel blood diagnostic marker for cholangiocarcinoma.EBioMedicine. 2019 Feb;40:422-431. doi: 10.1016/j.ebiom.2018.12.063. Epub 2019 Jan 9.
• [233] Expression and clinical significance of PIWIL2 in hilar cholangiocarcinoma tissues and cell lines.Genet Mol Res. 2015 Jun 26;14(2):7053-61. doi: 10.4238/2015.June.26.15.
• [234] lnc-PKD2-2-3, identified by long non-coding RNA expression profiling, is associated with pejorative tumor features and poor prognosis, enhances cancer stemness and may serve as cancer stem-cell marker in cholangiocarcinoma.Int J Oncol. 2019 Jul;55(1):45-58. doi: 10.3892/ijo.2019.4798. Epub 2019 May 6.
• [235] Polo-like kinase 3 is associated with improved overall survival in cholangiocarcinoma.Liver Int. 2015 Nov;35(11):2448-57. doi: 10.1111/liv.12839. Epub 2015 Apr 10.
• [236] Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma.Am J Cancer Res. 2019 Mar 1;9(3):546-561. eCollection 2019.
• [237] Podocalyxin-like protein 1 expression is useful to differentiate pancreatic ductal adenocarcinomas from adenocarcinomas of the biliary and gastrointestinal tracts.Hum Pathol. 2007 Feb;38(2):359-64. doi: 10.1016/j.humpath.2006.08.025. Epub 2006 Nov 29.
• [238] CXCL7 promotes proliferation and invasion of cholangiocarcinoma cells.Oncol Rep. 2017 Feb;37(2):1114-1122. doi: 10.3892/or.2016.5312. Epub 2016 Dec 12.
• [239] Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.Oncol Rep. 2014 Feb;31(2):983-8. doi: 10.3892/or.2013.2922. Epub 2013 Dec 13.
• [240] Mitochondrial division inhibitor-1 potentiates cisplatin-induced apoptosis via the mitochondrial death pathway in cholangiocarcinoma cells.Biomed Pharmacother. 2019 Mar;111:109-118. doi: 10.1016/j.biopha.2018.12.051. Epub 2018 Dec 19.
• [241] Peroxiredoxin 6 expression is inversely correlated with nuclear factor-B activation during Clonorchis sinensis infestation.Free Radic Biol Med. 2016 Oct;99:273-285. doi: 10.1016/j.freeradbiomed.2016.08.016. Epub 2016 Aug 20.
• [242] PRIMA-1(MET) Induces Cellular Senescence and Apoptotic Cell Death in Cholangiocarcinoma Cells.Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):543-552. doi: 10.21873/cgp.20156.
• [243] Altered regulation of Prox1-gene-expression in liver tumors.BMC Cancer. 2008 Apr 9;8:92. doi: 10.1186/1471-2407-8-92.
• [244] Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.J Hepatol. 2007 Nov;47(5):677-83. doi: 10.1016/j.jhep.2007.05.017. Epub 2007 Jun 27.
• [245] Secretomic profiling of cells from hollow fiber bioreactor reveals PSMA3 as a potential cholangiocarcinoma biomarker.Int J Oncol. 2017 Jul;51(1):269-280. doi: 10.3892/ijo.2017.4024. Epub 2017 May 29.
• [246] Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients.Gastroenterology. 2014 May;146(5):1397-407. doi: 10.1053/j.gastro.2014.01.062. Epub 2014 Feb 4.
• [247] Enhanced expression of RAD51 associating protein-1 is involved in the growth of intrahepatic cholangiocarcinoma cells.Clin Cancer Res. 2008 Mar 1;14(5):1333-9. doi: 10.1158/1078-0432.CCR-07-1381.
• [248] Sumoylation in p27kip1 via RanBP2 promotes cancer cell growth in cholangiocarcinoma cell line QBC939.BMC Mol Biol. 2017 Sep 7;18(1):23. doi: 10.1186/s12867-017-0100-5.
• [249] LncRNA-MEG3 inhibits cell proliferation and invasion by modulating Bmi1/RNF2 in cholangiocarcinoma.J Cell Physiol. 2019 Dec;234(12):22947-22959. doi: 10.1002/jcp.28856. Epub 2019 May 22.
• [250] Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells.Int J Cancer. 1992 Sep 9;52(2):252-60. doi: 10.1002/ijc.2910520217.
• [251] Comparative Proteomic Analysis of Human Cholangiocarcinoma Cell Lines: S100A2 as a Potential Candidate Protein Inducer of Invasion.Dis Markers. 2015;2015:629367. doi: 10.1155/2015/629367. Epub 2015 Apr 27.
• [252] The expression of HSP27 is associated with poor clinical outcome in intrahepatic cholangiocarcinoma.BMC Cancer. 2007 Dec 21;7:232. doi: 10.1186/1471-2407-7-232.
• [253] Temporary Balloon Occlusion for Hepatic Arterial Flow Redistribution during Yttrium-90 Radioembolization.J Vasc Interv Radiol. 2019 Aug;30(8):1201-1206. doi: 10.1016/j.jvir.2019.01.003. Epub 2019 May 30.
• [254] Mammaglobin B gene as a novel marker for lymph node micrometastasis in patients with abdominal cancers.Cancer Lett. 2000 Mar 13;150(1):79-84. doi: 10.1016/s0304-3835(99)00378-x.
• [255] Wild-type and splice-variant secretin receptors in lung cancer: overexpression in carcinoid tumors and peritumoral lung tissue.Mod Pathol. 2008 Apr;21(4):387-95. doi: 10.1038/modpathol.3801005. Epub 2008 Jan 25.
• [256] Allele loss and epigenetic inactivation of 3p21.3 in malignant liver tumors.Int J Cancer. 2005 Jul 10;115(5):684-9. doi: 10.1002/ijc.20944.
• [257] MART-10 represses cholangiocarcinoma cell growth and high vitamin D receptor expression indicates better prognosis for cholangiocarcinoma.Sci Rep. 2017 Mar 3;7:43773. doi: 10.1038/srep43773.
• [258] Role of stratifin (14-3-3 sigma) in adenocarcinoma of gallbladder: A novel prognostic biomarker.Surg Oncol. 2020 Mar;32:57-62. doi: 10.1016/j.suronc.2019.10.022. Epub 2019 Nov 2.
• [259] miR-191 Inhibition Induces Apoptosis Through Reactivating Secreted Frizzled-Related Protein-1 in Cholangiocarcinoma.Cell Physiol Biochem. 2018;49(5):1933-1942. doi: 10.1159/000493654. Epub 2018 Sep 20.
• [260] Genetic and expression alterations in association with the sarcomatous change of cholangiocarcinoma cells.Exp Mol Med. 2009 Feb 28;41(2):102-15. doi: 10.3858/emm.2009.41.2.013.
• [261] Sirtuin7 has an oncogenic potential via promoting the growth of cholangiocarcinoma cells.Biomed Pharmacother. 2018 Apr;100:257-266. doi: 10.1016/j.biopha.2018.02.007. Epub 2018 Feb 16.
• [262] SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma.J Hepatol. 2017 Jul;67(1):72-83. doi: 10.1016/j.jhep.2017.02.017. Epub 2017 Feb 22.
• [263] Comparative proteomic profiling of human bile reveals SSP411 as a novel biomarker of cholangiocarcinoma.PLoS One. 2012;7(10):e47476. doi: 10.1371/journal.pone.0047476. Epub 2012 Oct 31.
• [264] Ars2 is overexpressed in human cholangiocarcinomas and its depletion increases PTEN and PDCD4 by decreasing microRNA-21.Mol Carcinog. 2013 Apr;52(4):286-96. doi: 10.1002/mc.21859. Epub 2011 Dec 28.
• [265] A novel TFF2 splice variant (EX2TFF2) correlates with longer overall survival time in cholangiocarcinoma.Oncol Rep. 2012 Apr;27(4):1207-12. doi: 10.3892/or.2011.1583. Epub 2011 Dec 7.
• [266] Silencing of Tousled-like kinase 1 sensitizes cholangiocarcinoma cells to cisplatin-induced apoptosis.Cancer Lett. 2010 Oct 1;296(1):27-34. doi: 10.1016/j.canlet.2010.03.011. Epub 2010 Apr 9.
• [267] Suppression of thymosin 10 increases cell migration and metastasis of cholangiocarcinoma.BMC Cancer. 2013 Sep 23;13:430. doi: 10.1186/1471-2407-13-430.
• [268] [Corrigendum] Genetic and epigenetic alterations are involved in the regulation of TPM1 in cholangiocarcinoma.Int J Oncol. 2017 Jan;50(1):340. doi: 10.3892/ijo.2016.3749. Epub 2016 Oct 24.
• [269] Tetraspanin 1 promotes epithelial-to-mesenchymal transition and metastasis of cholangiocarcinoma via PI3K/AKT signaling.J Exp Clin Cancer Res. 2018 Dec 4;37(1):300. doi: 10.1186/s13046-018-0969-y.
• [270] Block of NF-kB signaling accelerates MYC-driven hepatocellular carcinogenesis and modifies the tumor phenotype towards combined hepatocellular cholangiocarcinoma.Cancer Lett. 2019 Aug 28;458:113-122. doi: 10.1016/j.canlet.2019.05.023. Epub 2019 May 22.